Aclarion, Inc.

Aclarion, Inc. is a healthcare technology company dedicated to advancing the care of patients suffering from chronic lower back pain. The company's mission is to deliver noninvasive, evidence-based, SaaS solutions that empower physicians to create personalized treatment plans, aiming to improve clinical outcomes and help patients return to a life free from back pain. Headquartered in Broomfield, Colorado, Aclarion operates at the intersection of medical imaging and artificial intelligence.

The company's flagship product is NOCISCAN, a proprietary Software-as-a-Service (SaaS) platform. NOCISCAN leverages Magnetic Resonance Spectroscopy (MRS) capabilities of existing MRI scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. Through proprietary signal-processing biomarkers and augmented intelligence (AI) algorithms, NOCISCAN identifies chemical biomarkers associated with degenerative pain and structural integrity of lumbar discs. The platform includes NOCICALC, a Class I medical device for post-processing raw MRS data, and NOCIGRAM, which processes results into individualized NOCISCORES to indicate potential sources of pain.

Led by CEO Brent Ness, who was appointed in September 2021, Aclarion has recently reported strong Q1 2026 results, demonstrating 196% annual scan volume growth. The company secured a U.S. Patent (#12,601,803) in April 2026 for its AI-driven MRS data analysis platform, expanding its intellectual property portfolio. Aclarion also announced a $2.5 million stock repurchase plan and an agreement with Weill Cornell Medicine in April 2026. The ongoing CLARITY trial, a pivotal multi-site randomized study, is expected to provide initial readouts in Q4 2026, further solidifying NOCISCAN's market positioning as a leading non-invasive diagnostic tool for chronic low back pain.

Latest updates

Aclarion Expands Weill Cornell Partnership with Second Nociscan Trial

Event summary

  • Aclarion secures second commercial agreement with Weill Cornell Medicine for Nociscan platform.
  • Trial led by neurosurgeon Roger Härtl to study lumbar microdiscectomy with bone marrow aspirate concentrate.
  • Study aims to evaluate long-term effects on degenerative disc disease over 2 years.
  • Nociscan demonstrates 97% surgical success rate when all identified pain-positive discs are treated.

The big picture

Aclarion's deepening collaboration with Weill Cornell Medicine underscores the growing interest in AI-driven diagnostic tools for chronic low back pain. With 266 million people worldwide suffering from degenerative spine disease, the success of Nociscan could reshape treatment protocols and improve surgical outcomes. The trial's focus on bone marrow aspirate concentrate injections highlights the intersection of regenerative medicine and precision diagnostics.

What we're watching

Clinical Validation
Whether the trial results will further validate Nociscan's efficacy in identifying pain sources in degenerative disc disease.
Market Expansion
The pace at which Aclarion can secure additional high-profile partnerships to expand Nociscan's reach.
Regulatory Pathway
How the data from this trial may influence future regulatory approvals or reimbursement discussions.

Aclarion's Scan Volume Triples, Signaling Nociscan Adoption Momentum

Event summary

  • Aclarion reported Q1 2026 scan volumes increased 196% year-over-year, with 64% sequential growth.
  • The company has secured reimbursement from Vitality, AXA, and Aviva in the UK.
  • A $2.5 million share repurchase program was announced.
  • Aclarion holds $19.0 million in cash with no debt and expects this to fund operations through mid-2027.
  • A new AI patent was issued, expanding Aclarion’s intellectual property portfolio to 64 issued and pending patents.

The big picture

Aclarion's rapid scan volume growth validates the Nociscan platform's potential to disrupt the lumbar MRI market, which represents a $2 billion opportunity. The company's early success in the UK, driven by reimbursement and direct-to-patient marketing, provides a blueprint for expansion in the US. However, the company's valuation will be heavily dependent on clinical trial results and payer adoption.

What we're watching

Reimbursement Expansion
The pace of US payer adoption will be critical to Aclarion’s ability to scale, and the company's Reimbursement Program's success will be a key indicator of future revenue.
Clinical Trial Data
The CLARITY trial interim readout in late 2026 will be a pivotal moment, as positive results could significantly accelerate adoption and reimbursement.
Growth Sustainability
Whether Aclarion can maintain its high sequential growth rate (64%) as it expands into larger markets will determine the long-term viability of its business model.

Aclarion Bolsters Sales Team as Nociscan Adoption Accelerates

Event summary

  • Aclarion appointed Daniel Keefe as Commercial Director for the Western U.S., effective immediately.
  • Keefe brings over 20 years of experience in medical device and healthcare technology sales, most recently from Centinel Spine.
  • Aclarion reports triple-digit growth in Nociscan utilization, driving the expansion of its commercial team.
  • Nociscan has a reported 97% surgical success rate when all Nociscan-positive discs are treated.
  • Aclarion’s Nociscan platform addresses the chronic low back pain market, impacting an estimated 266 million people globally.

The big picture

Aclarion’s aggressive expansion signals growing confidence in Nociscan's ability to disrupt the chronic low back pain diagnostics market. The appointment of a seasoned commercial leader like Keefe suggests the company is prioritizing rapid market penetration over profitability in the near term. This strategy carries inherent risks, as reliance on a single product and region exposes Aclarion to competitive pressures and potential regulatory hurdles.

What we're watching

Sales Execution
Keefe’s track record will be critical; investors should monitor whether he can replicate his success at Centinel Spine in driving Nociscan adoption across Aclarion’s Western U.S. territories.
Clinical Integration
The pace at which Nociscan integrates into standard clinical workflows will dictate its long-term market penetration, and requires continued engagement with both academic institutions and private practices.
Competitive Landscape
Given Keefe’s experience with competitors like Intuitive Surgical and Zimmer Biomet, Aclarion must anticipate and counter competitive responses to Nociscan’s growing market share.
CID: 2935